Regulatory & Legal

Modest growth is forecast, but Canada's economy faces a pivotal year as federal stimulus clashes with looming CUSMA renegotiations and U.S. headwinds.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

The Oncology Institute promotes new CIO and CPO, signaling a strategic push into AI-driven care and robust talent management to dominate the market.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.

A new study reveals the hidden quality-of-life toll of a common virus on transplant patients, highlighting the urgent need for targeted new therapies.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

With a new board chair, regulatory backing, and an AI platform, GC Therapeutics is targeting MS and diabetes with next-generation cell therapies.

Thousands of parents will explore a burgeoning marketplace of school options in Las Vegas, from public charters to private academies, amid new state policies.

Surging NYC energy bills have homeowners facing a tough choice. Learn the key signs that your aging HVAC system needs replacement, not another costly repair.

Facing a Nasdaq delisting notice, Chinese office provider Ucommune plans drastic measures amid dire financials and a saturated real estate market.

Backed by CRISPR pioneers and $16M, a new biotech aims to make personalized gene therapies a scalable reality for millions with rare genetic disorders.

Kezar Life Sciences faces a critical FDA meeting for its novel liver disease drug, a decision that could bring hope to patients and define the company's future.

Amid a major corporate restructure, Atos partners with the World DanceSport Federation, betting on tech to transform the ballroom and secure its market lead.

Sanuwave Health posts record revenue, defying industry-wide turmoil as reimbursement cuts reshape the advanced wound care market. How did they do it?

A 2.9 MEUR deal for GomSpace to design lunar spacecraft for a major North American firm signals a new era for small satellites in deep space exploration.

As 2026 begins, the crypto market sees a split personality: a wild memecoin surge alongside a steady, tech-driven recovery in the AI sector.

A 70-year-old infrastructure giant launches a new power company, aiming to redefine grid projects with an integrated, civil-first approach.